MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 289 filers reported holding MYRIAD GENETICS INC in Q2 2014. The put-call ratio across all filers is 3.64 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $75,316,000 | -47.1% | 3,659,647 | -21.4% | 1.33% | -54.8% |
| Q2 2016 | $142,422,000 | -29.6% | 4,654,327 | -13.9% | 2.94% | -22.0% |
| Q1 2016 | $202,259,000 | -27.4% | 5,403,662 | -16.3% | 3.77% | -31.8% |
| Q4 2015 | $278,776,000 | +9.7% | 6,459,139 | -4.8% | 5.53% | +1.4% |
| Q3 2015 | $254,236,000 | +15.3% | 6,783,252 | +4.6% | 5.45% | +27.4% |
| Q2 2015 | $220,467,000 | +7.2% | 6,486,226 | +11.6% | 4.28% | -3.7% |
| Q1 2015 | $205,667,000 | +44.6% | 5,809,799 | +39.1% | 4.45% | +67.8% |
| Q4 2014 | $142,237,000 | +43.4% | 4,176,074 | +62.4% | 2.65% | +31.0% |
| Q3 2014 | $99,201,000 | -10.6% | 2,571,961 | -9.8% | 2.02% | -29.3% |
| Q2 2014 | $110,971,000 | +39.3% | 2,851,267 | +22.4% | 2.86% | +13.3% |
| Q1 2014 | $79,661,000 | +398.0% | 2,329,953 | +205.6% | 2.52% | +418.5% |
| Q4 2013 | $15,995,000 | – | 762,400 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |